Literature DB >> 30027154

Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance.

Erin M Wesley1, Gang Xin2, Donna McAllister1, Subramaniam Malarkannan1,2,3,4, Debra K Newman2,5, Michael B Dwinell1, Weiguo Cui1,2, Bryon D Johnson1,4, Matthew J Riese1,2,3.   

Abstract

Targeting negative regulators downstream of the T cell receptor (TCR) represents a novel strategy to improve cancer immunotherapy. Two proteins that serve as critical inhibitory regulators downstream of the TCR are diacylglycerol kinase ζ (DGKζ), a regulator of Ras and PKC-θ signaling, and Casitas b-lineage proto-oncogene b (Cbl-b), an E3 ubiquitin ligase that predominantly regulates PI(3)K signaling. We sought to compare the signaling and functional effects that result from deletion of DGKζ, Cbl-b, or both (double knockout, DKO) in T cells, and to evaluate tumor responses generated in a clinically relevant orthotopic pancreatic tumor model. We found that whereas deletion of Cbl-b primarily served to enhance NF-κB signaling, deletion of DGKζ enhanced TCR-mediated signal transduction downstream of Ras/Erk and NF-κB. Deletion of DGKζ or Cbl-b comparably enhanced CD8+ T cell functional responses, such as proliferation, production of IFNγ, and generation of granzyme B when compared with WT T cells. DKO T cells demonstrated enhanced function above that observed with single knockout T cells after weak, but not strong, stimulation. Deletion of DGKζ, but not Cbl-b, however, resulted in significant increases in numbers of activated (CD44hi) CD8+ T cells in both non-treated and tumor-bearing mice. DGKζ-deficient mice also had enhanced control of pancreatic tumor cell growth compared to Cbl-b-deficient mice. This represents the first direct comparison between mice of these genotypes and suggests that T cell immunotherapies may be better improved by targeting TCR signaling molecules that are regulated by DGKζ as opposed to molecules regulated by Cbl-b.

Entities:  

Keywords:  Cbl-b; Diacylglycerol kinase zeta; T cell activation; TCR signal transduction; tumor immunology

Year:  2018        PMID: 30027154      PMCID: PMC6048965          DOI: 10.4049/immunohorizons.1700055

Source DB:  PubMed          Journal:  Immunohorizons        ISSN: 2573-7732


  44 in total

1.  Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells.

Authors:  D Fang; H Y Wang; N Fang; Y Altman; C Elly; Y C Liu
Journal:  J Biol Chem       Date:  2000-11-21       Impact factor: 5.157

2.  TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β.

Authors:  Vidhyalakshmi Arumugam; Theresa Bluemn; Erin Wesley; Amanda M Schmidt; Taku Kambayashi; Subramaniam Malarkannan; Matthew J Riese
Journal:  J Leukoc Biol       Date:  2015-07-07       Impact factor: 4.962

3.  Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b.

Authors:  K Bachmaier; C Krawczyk; I Kozieradzki; Y Y Kong; T Sasaki; A Oliveira-dos-Santos; S Mariathasan; D Bouchard; A Wakeham; A Itie; J Le; P S Ohashi; I Sarosi; H Nishina; S Lipkowitz; J M Penninger
Journal:  Nature       Date:  2000-01-13       Impact factor: 49.962

4.  An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T cells.

Authors:  Weiguo Cui; Ying Liu; Jason S Weinstein; Joseph Craft; Susan M Kaech
Journal:  Immunity       Date:  2011-11-23       Impact factor: 31.745

5.  Decreased diacylglycerol metabolism enhances ERK activation and augments CD8+ T cell functional responses.

Authors:  Matthew J Riese; Jashanpreet Grewal; Jayajit Das; Tao Zou; Vineet Patil; Arup K Chakraborty; Gary A Koretzky
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

6.  The ζ isoform of diacylglycerol kinase plays a predominant role in regulatory T cell development and TCR-mediated ras signaling.

Authors:  Rohan P Joshi; Amanda M Schmidt; Jayajit Das; Dariusz Pytel; Matthew J Riese; Melissa Lester; J Alan Diehl; Edward M Behrens; Taku Kambayashi; Gary A Koretzky
Journal:  Sci Signal       Date:  2013-11-26       Impact factor: 8.192

Review 7.  Cancer immunotherapy: harnessing the immune system to battle cancer.

Authors:  Yiping Yang
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

8.  Enhanced T cell responses due to diacylglycerol kinase zeta deficiency.

Authors:  Xiao-Ping Zhong; Ehmonie A Hainey; Benjamin A Olenchock; Martha S Jordan; Jonathan S Maltzman; Kim E Nichols; Hao Shen; Gary A Koretzky
Journal:  Nat Immunol       Date:  2003-07-27       Impact factor: 25.606

9.  Ablation of Cbl-b provides protection against transplanted and spontaneous tumors.

Authors:  Jeffrey Y Chiang; Ihn Kyung Jang; Richard Hodes; Hua Gu
Journal:  J Clin Invest       Date:  2007-03-15       Impact factor: 14.808

10.  Control of virus-specific CD8+ T-cell exhaustion and immune-mediated pathology by E3 ubiquitin ligase Cbl-b during chronic viral infection.

Authors:  Rong Ou; Menghua Zhang; Lei Huang; Demetrius Moskophidis
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

View more
  6 in total

Review 1.  Enhancing a Natural Killer: Modification of NK Cells for Cancer Immunotherapy.

Authors:  Rasa Islam; Aleta Pupovac; Vera Evtimov; Nicholas Boyd; Runzhe Shu; Richard Boyd; Alan Trounson
Journal:  Cells       Date:  2021-04-29       Impact factor: 6.600

Review 2.  E3 ubiquitin ligase Casitas B lineage lymphoma-b and its potential therapeutic implications for immunotherapy.

Authors:  D Jafari; M J Mousavi; S Keshavarz Shahbaz; L Jafarzadeh; S Tahmasebi; J Spoor; A Esmaeilzadeh
Journal:  Clin Exp Immunol       Date:  2021-01-10       Impact factor: 5.732

Review 3.  Manipulating the TCR signaling network for cellular immunotherapy: Challenges & opportunities.

Authors:  Courtney A Matson; Nevil J Singh
Journal:  Mol Immunol       Date:  2020-05-15       Impact factor: 4.174

Review 4.  Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity.

Authors:  Poojitha Sitaram; Bradley Uyemura; Subramaniam Malarkannan; Matthew J Riese
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923

5.  Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes.

Authors:  Javier Arranz-Nicolás; Miguel Martin-Salgado; Cristina Rodríguez-Rodríguez; Rosa Liébana; Maria C Moreno-Ortiz; Judith Leitner; Peter Steinberger; Antonia Ávila-Flores; Isabel Merida
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

6.  DGKζ exerts greater control than DGKα over CD8+ T cell activity and tumor inhibition.

Authors:  Junchen Gu; Cindy Wang; Carolyn Cao; Jinwen Huang; Sandra Holzhauer; Heshani Desilva; Erin M Wesley; Douglas B Evans; Joseph Benci; Michael Wichroski; Susan Wee; Matthew J Riese
Journal:  Oncoimmunology       Date:  2021-07-21       Impact factor: 8.110

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.